Therapeutic monoclonal antibodies (mAbs) are glycoproteins produced by living cell systems. Glycosylation is one of the most common post-translational modifications (PTMs) of proteins.https://www.creativebiolabs.net/glycosylation-analysis-of-therapeutic-glycoproteins.htm

1. CREATIVE BIOLABS • RECOMBINANT ANTIBODY
45-1 Ramsey Road, Shirley, NY 11967, USA
Email: info@creative-biolabs.com
4 / 20
Mechanism of Action (MoAs) for Therapeutic Antibodies – provide
novel therapeutic monoclonal antibodies discovery direction
and various mAb-based therapy strategies
The complexity of cancer and other diseases calls for the development of multiple antibody‐based drugs
for even a single disease target. With the development of genetic engineering and screening methods,
researchers are able to design and engineer antibody drug on the basis of comprehending the
mechanisms of action (MoAs) of therapeutic antibodies. A better understanding of antibody‐based
MoAs have led to the expansion of pharmaceuticals with increased potency and greater precision.
Antibody‐based drugs work via multiple mechanisms, recapitulating some of the many mechanisms
observed in the immune system. The ability to design and engineer novel Ab molecules has greatly
expanded their range. Known MoAs for therapeutic antibodies include(i) blocking or neutralizing:
disruption of ligand–receptor interaction; (ii) target cell elimination via antibody‐dependent cellular
cytotoxicity(ADCC), complement‐dependent cytotoxicity (CDC), and antibody‐dependent cellular
phagocytosis (ADCP); (iii) engagement of cytotoxicT cell by bispecific antibodies or chimeric antigen
receptor T cells (cart cells); (iv) receptor down regulation by enhanced internalization and degradation;
and(v) targeted drug delivery (Fig. 2). Antitumor antibodies can target tumors either directly or indirectly
and exemplify many of these MoAs. Here, we review these mechanisms using some examples of a
number of therapeutic antibody drug development strategies used in cancer treatment (Fig. 2).There
are various evaluated strategies, including using immunoglobulin G (IgG) to target cancer directly, alter
the host response to cancer, deliver cytotoxic substances to cancer and retarget the cellular immune
response towards cancer.